TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China

被引:1
作者
Huang, Mingxing [1 ]
Lin, Guoli [2 ]
Shi, Hong [2 ]
Wu, Yuankai [2 ]
Jie, Yusheng [1 ]
Zhu, Zhe [3 ]
Chong, Yutian [2 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Infect Dis, Zhuhai, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Infect Dis, Guangzhou, Guangdong, Peoples R China
[3] Cleveland Clin, Lerner Res Inst, Dept Stem Cell Biol & Regenerat Med, Cleveland, OH 44195 USA
关键词
TENOFOVIR DISOPROXIL FUMARATE; LONG-TERM EFFICACY; ADEFOVIR DIPIVOXIL; VIRUS; ENTECAVIR; FAILURE; COHORT;
D O I
10.1155/2017/2463197
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background/Aims. Many patients had to transfer to tenofovir disoproxil fumarate (TDF) if there is other nucleos(t)ide analogue (NA) resistance. We aimed to investigate antiviral effects of TDF monotherapy between NA-naive and NA-experienced chronic hepatitis B (CHB) patients in China. Methods. A total of 102 NA-naive and NA-experienced CHB patients with TDF monotherapy (300 mg/day) were retrospectively analyzed for useful parameters up to 72 weeks. Results. There were 36 and 66 patients with matched HBV DNA baseline level in NA-naive and NA-experienced group, respectively. There were no significant differences between NA-naive and NA-experienced groups in HBV DNA levels (all P > 0.05) and HBV DNA undetectable rates (all P > 0.05) at all time points. At the end of follow-up, HBV DNA undetectable rates in NA-naive and NA-experienced group were 96.2% (25/26) and 91.8% (45/49), respectively (P = 0.476). Baseline HBV DNA level was the only independent predictor for HBV DNA negative time (P = 0.018). In addition, 27.8% (5/18) and 11.4% (4/35) achieved HBeAg seroconversion at the end of the follow-up, respectively (P = 0.133). Conclusions. TDF monotherapy was effective regardless of prior NA experienced. Baseline HBV DNA was a key predictive factor for HBV DNA negative time in TDF monotherapy.
引用
收藏
页数:8
相关论文
共 23 条
  • [1] Assessing long-term treatment efficacy in chronic hepatitis B and C: Between evidence and common sense
    Aghemo, Alessio
    Lampertico, Pietro
    Colombo, Massimo
    [J]. JOURNAL OF HEPATOLOGY, 2012, 57 (06) : 1326 - 1335
  • [2] Efficacy of Tenofovir in Patients with Lamivudine Failure Is Not Different from That in Nucleoside/Nucleotide Analogue-Naive Patients with Chronic Hepatitis B
    Baran, Bulent
    Soyer, Ozlem Mutluay
    Ormeci, Asli Cifcibasi
    Gokturk, Suut
    Evirgen, Sami
    Bozbey, Hamza Ugur
    Akyuz, Filiz
    Karaca, Cetin
    Demir, Kadir
    Besisik, Fatih
    Onel, Derya
    Gulluoglu, Mine
    Badur, Selim
    Kaymakoglu, Sabahattin
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (04) : 1790 - 1796
  • [3] Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
    Chen, CJ
    Yang, HI
    Su, J
    Jen, CL
    You, SL
    Lu, SN
    Huang, GT
    Iloeje, UH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01): : 65 - 73
  • [4] Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections
    De Clercq, Erik
    Ferir, Geoffrey
    Kaptein, Suzanne
    Neyts, Johan
    [J]. VIRUSES-BASEL, 2010, 2 (06): : 1279 - 1305
  • [5] Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir
    Fong, Tse-Ling
    Tien, Andy
    Jo, Kahee J.
    Chu, Danny
    Cheung, Eddie
    Mena, Edward A.
    Quang-Quoc Phan
    Yu, Andy S.
    Mohammed, Wafa
    Velasco, Andrew
    Vinh-Huy LeDuc
    Nguyen, Nickolas
    Han, Steven-Bui
    Chang, Mimi
    Bae, Ho S.
    Cho, Yong-Won
    Tong, Myron J.
    Cooper, Stewart L.
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (11) : 3465 - 3472
  • [6] Renal Function in Chronic Hepatitis B Patients Treated With Tenofovir Disoproxil Fumarate or Entecavir Monotherapy A Matched Case-Cohort Study
    Ha, Nghi B.
    Ku, Kevin
    Ha, Nghiem B.
    Chaung, Kevin T.
    Trinh, Huy N.
    Nguyen, Mindie H.
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2015, 49 (10) : 873 - 877
  • [7] Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: Week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103)
    Heathcote, J.
    George, J.
    Gordon, S.
    Bronowicki, J. P.
    Sperl, J.
    Williams, R.
    Martin, P.
    Beniowski, M.
    Sorbel, J.
    Anderson, J.
    Mondou, E.
    Snow, A.
    Rousseau, F.
    [J]. JOURNAL OF HEPATOLOGY, 2008, 48 : S32 - S32
  • [8] INHIBITORY EFFECTS OF ACYCLIC NUCLEOSIDE PHOSPHONATES ON HUMAN HEPATITIS-B VIRUS AND DUCK HEPATITIS-B VIRUS-INFECTIONS IN TISSUE-CULTURE
    HEIJTINK, RA
    KRUINING, J
    DEWILDE, GA
    BALZARINI, J
    DECLERCQ, E
    SCHALM, SW
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (09) : 2180 - 2182
  • [9] Long-Term Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleos(t)ide-Experienced Chronic Hepatitis B Patients
    Huang, Mingxing
    Jie, Yusheng
    Lin, Guoli
    Shi, Hong
    Li, Xinhua
    Li, Xiangyong
    Wu, Yuankai
    Chong, Yutian
    [J]. CLINICAL DRUG INVESTIGATION, 2016, 36 (06) : 471 - 478
  • [10] Huang MX, 2015, INT J CLIN EXP MED, V8, P666